<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38958301</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>ACG Clinical Guideline: Focal Liver Lesions.</ArticleTitle><Pagination><StartPage>1235</StartPage><EndPage>1271</EndPage><MedlinePgn>1235-1271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000002857</ELocationID><Abstract><AbstractText>Focal liver lesions (FLLs) have become an increasingly common finding on abdominal imaging, especially asymptomatic and incidental liver lesions. Gastroenterologists and hepatologists often see these patients in consultation and make recommendations for management of multiple types of liver lesions, including hepatocellular adenoma, focal nodular hyperplasia, hemangioma, and hepatic cystic lesions including polycystic liver disease. Malignancy is important to consider in the differential diagnosis of FLLs, and healthcare providers must be familiar with the diagnosis and management of FLLs. This American College of Gastroenterology practice guideline uses the best evidence available to make diagnosis and management recommendations for the most common FLLs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by The American College of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frenette</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2245-8173</Identifier><AffiliationInfo><Affiliation>Family Health Centers of San Diego, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendiratta-Lala</LastName><ForeName>Mishal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salgia</LastName><ForeName>Reena</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology/Hepatology, Henry Ford Health, Detroit, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System and Stanford University School of Medicine, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauer</LastName><ForeName>Bryan G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillai</LastName><ForeName>Anjana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago Medical Center, University of Chicago, Chicago, Illinois, USA .</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C536330">Polycystic liver disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020518" MajorTopicYN="Y">Focal Nodular Hyperplasia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="Y">Liver Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006391" MajorTopicYN="Y">Hemangioma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003560" MajorTopicYN="Y">Cysts</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018248" MajorTopicYN="Y">Adenoma, Liver Cell</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005762" MajorTopicYN="N">Gastroenterology</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>3</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38958301</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000002857</ArticleId><ArticleId IdType="pii">00000434-202407000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924&#x2013;6.</Citation></Reference><Reference><Citation>Balshem H, Helfand M, Sch&#xfc;nemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64(4):401&#x2013;6.</Citation></Reference><Reference><Citation>Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one: Grading the evidence. Clin Gastroenterol Hepatol 2013;11(4):329&#x2013;32.</Citation></Reference><Reference><Citation>American College of Radiology Committee on LI-RADS (Liver). LIRADS Lexicon Table. ( https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LIRADS-Lexicon-Table.pdf ). Accessed April 3, 2023.</Citation></Reference><Reference><Citation>Smith-Bindman R, Kwan ML, Marlow EC, et al. Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000-2016. JAMA 2019;322(9):843&#x2013;56.</Citation></Reference><Reference><Citation>Washington K. Masses of the liver. In: Goldblum JR, Odze RD (eds). Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd edn. Saunders, an imprint of Elsevier: Philadelphia, PA, 2009, pp 657&#x2013;789.</Citation></Reference><Reference><Citation>Kaltenbach TE, Engler P, Kratzer W, et al. Prevalence of benign focal liver lesions: Ultrasound investigation of 45,319 hospital patients. Abdom Radiol (NY) 2016;41(1):25&#x2013;32.</Citation></Reference><Reference><Citation>Li J, Wang J, Lei L, et al. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: A meta-analysis of eight prospective studies. Eur Radiol 2019;29(12):6519&#x2013;28.</Citation></Reference><Reference><Citation>Wang J, Ye X, Li J, et al. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100(6):e24602.</Citation></Reference><Reference><Citation>Margolis NE, Shaver CM, Rosenkrantz AB. Indeterminate liver and renal lesions: Comparison of computed tomography and magnetic resonance imaging in providing a definitive diagnosis and impact on recommendations for additional imaging. J Comput Assist Tomogr 2013;37(6):882&#x2013;6.</Citation></Reference><Reference><Citation>Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: International multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009;15(30):3748&#x2013;56.</Citation></Reference><Reference><Citation>Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68(2):723&#x2013;50.</Citation></Reference><Reference><Citation>Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289(3):816&#x2013;30.</Citation></Reference><Reference><Citation>Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421&#x2013;30.</Citation></Reference><Reference><Citation>Pomfret EA, Washburn K, Wald C, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16(3):262&#x2013;78.</Citation></Reference><Reference><Citation>Sporea I, S&#x103;ndulescu DL, &#x15e;irli R, et al. Contrast-enhanced ultrasound for the characterization of malignant versus benign focal liver lesions in a prospective multicenter experience: The SRUMB study. J Gastrointestin Liver Dis 2019;28:191&#x2013;6.</Citation></Reference><Reference><Citation>Elbanna KY, Kielar AZ. Computed tomography versus magnetic resonance imaging for hepatic lesion characterization/diagnosis. Clin Liver Dis (Hoboken) 2021;17(3):159&#x2013;64.</Citation></Reference><Reference><Citation>Ippolito D, Inchingolo R, Grazioli L, et al. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol 2018;24(23):2413&#x2013;26.</Citation></Reference><Reference><Citation>Inchingolo R, Faletti R, Grazioli L, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol 2018;10(7):462&#x2013;73.</Citation></Reference><Reference><Citation>Oldhafer KJ, Habbel V, Horling K, et al. Benign liver tumors. Visc Med 2020;36(4):292&#x2013;303.</Citation></Reference><Reference><Citation>Zhang L, Yu X, Huo L, et al. Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: Systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI. Eur Radiol 2019;29(10):5205&#x2013;16.</Citation></Reference><Reference><Citation>Wang G, Zhu S, Li X. Comparison of values of CT and MRI imaging in the diagnosis of hepatocellular carcinoma and analysis of prognostic factors. Oncol Lett 2019;17(1):1184&#x2013;8.</Citation></Reference><Reference><Citation>Suh CH, Kim KW, Park SH, et al. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. Eur Radiol 2018;28(1):214&#x2013;25.</Citation></Reference><Reference><Citation>Kim SY, Park SH, Wu EH, et al. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: Risk factor analyses. AJR Am J Roentgenol 2015;204(6):1220&#x2013;7.</Citation></Reference><Reference><Citation>Davenport MS, Viglianti BL, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: Effect on arterial phase image quality. Radiology 2013;266(2):452&#x2013;61.</Citation></Reference><Reference><Citation>Zhang J, Mavros MN, Cosgrove D, et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol 2013;20(2):e123&#x2013;31.</Citation></Reference><Reference><Citation>Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;242(7):644&#x2013;8.</Citation></Reference><Reference><Citation>Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349(15):1443&#x2013;50.</Citation></Reference><Reference><Citation>Heinemann K, Thiel C, M&#xf6;hner S, et al. Benign gynecological tumors: Estimated incidence. Results of the German Cohort Study on Women's Health. Eur J Obstet Gynecol Reprod Biol 2003;107(1):78&#x2013;80.</Citation></Reference><Reference><Citation>Edmondson HA, Reynolds TB, Henderson B, et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977;86(2):180&#x2013;2.</Citation></Reference><Reference><Citation>B&#xfc;hler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982;82(4):775&#x2013;82.</Citation></Reference><Reference><Citation>Martin NM, Abu Dayyeh BK, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008;14(28):4573&#x2013;5.</Citation></Reference><Reference><Citation>Bunchorntavakul C, Bahirwani R, Drazek D, et al. Clinical features and natural history of hepatocellular adenomas: The impact of obesity. Aliment Pharmacol Ther 2011;34(6):664&#x2013;74.</Citation></Reference><Reference><Citation>Socas L, Zumbado M, P&#xe9;rez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: A report of two cases and a review of the literature. Br J Sports Med 2005;39(5):e27.</Citation></Reference><Reference><Citation>Coombes GB, Reiser J, Paradinas FJ, et al. An androgen-associated hepatic adenoma in a trans-sexual. Br J Surg 1978;65(12):869&#x2013;70.</Citation></Reference><Reference><Citation>Bioulac-Sage P, Taouji S, Possenti L, et al. Hepatocellular adenoma subtypes: The impact of overweight and obesity. Liver Int 2012;32(8):1217&#x2013;21.</Citation></Reference><Reference><Citation>Oudmaijer CAJ, Berk KA, van der Louw E, et al. KETOgenic diet therapy in patients with HEPatocellular adenoma: Study protocol of a matched interventional cohort study. BMJ Open 2022;12(2):e053559.</Citation></Reference><Reference><Citation>Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: A series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24(3):276&#x2013;9.</Citation></Reference><Reference><Citation>Sakellariou S, Al-Hussaini H, Scalori A, et al. Hepatocellular adenoma in glycogen storage disorder type I: A clinicopathological and molecular study. Histopathology 2012;60(6b):E58&#x2013;65.</Citation></Reference><Reference><Citation>Visser G, Rake JP, Labrune P, et al. Consensus guidelines for management of glycogen storage disease type 1b: European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002;161(Suppl 1):S120&#x2013;3.</Citation></Reference><Reference><Citation>Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985;89(5):1132&#x2013;8.</Citation></Reference><Reference><Citation>Barbier L, Nault JC, Dujardin F, et al. Natural history of liver adenomatosis: A long-term observational study. J Hepatol 2019;71(6):1184&#x2013;92.</Citation></Reference><Reference><Citation>Bieze M, van den Esschert JW, Nio CY, et al. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: Prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 2012;199(1):26&#x2013;34.</Citation></Reference><Reference><Citation>Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology 2006;43(3):515&#x2013;24.</Citation></Reference><Reference><Citation>Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011;60(1):85&#x2013;9.</Citation></Reference><Reference><Citation>van Aalten SM, de Man RA, IJzermans JN, et al. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg 2012;99(7):911&#x2013;6.</Citation></Reference><Reference><Citation>Bieze M, Phoa SS, Verheij J, et al. Risk factors for bleeding in hepatocellular adenoma. Br J Surg 2014;101(7):847&#x2013;55.</Citation></Reference><Reference><Citation>Dokmak S, Belghiti J. Will weight loss become a future treatment of hepatocellular adenoma in obese patients? Liver Int 2015;35(10):2228&#x2013;32.</Citation></Reference><Reference><Citation>Gevers TJG, Marcel Spanier BW, Veendrick PB, et al. Regression of hepatocellular adenoma after bariatric surgery in severe obese patients. Liver Int 2018;38(12):2134&#x2013;6.</Citation></Reference><Reference><Citation>Silva TS, Sung M, Nelson DW, et al. A multicenter, 10-year experience with hepatocellular adenoma: Risk factors and disease course. Am Surg 2022;88(9):2345&#x2013;50.</Citation></Reference><Reference><Citation>Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: Imaging and pathologic findings. Radiographics 2001;21(4):877&#x2013;92; discussion 892&#x2013;4.</Citation></Reference><Reference><Citation>Ba-Ssalamah A, Antunes C, Feier D, et al. Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology 2015;277(1):104&#x2013;13.</Citation></Reference><Reference><Citation>Reizine E, Mul&#xe9; S, Luciani A. Focal benign liver lesions and their diagnostic pitfalls. Radiol Clin North Am 2022;60(5):755&#x2013;73.</Citation></Reference><Reference><Citation>Kim H, Park YN. Hepatocellular adenomas: Recent updates. J Pathol Transl Med 2021;55(3):171&#x2013;80.</Citation></Reference><Reference><Citation>Lagana SM, Salomao M, Bao F, et al. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol 2013;21(2):170&#x2013;6.</Citation></Reference><Reference><Citation>Choi WT, Kakar S. Atypical hepatocellular neoplasms: Review of clinical, morphologic, immunohistochemical, molecular, and cytogenetic features. Adv Anat Pathol 2018;25(4):254&#x2013;62.</Citation></Reference><Reference><Citation>Nault JC, Fabre M, Couchy G, et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012;56(1):184&#x2013;91.</Citation></Reference><Reference><Citation>Nault JC, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 2017;152(4):880&#x2013;94.e6.</Citation></Reference><Reference><Citation>Tse JR, Felker ER, Naini BV, et al. Hepatocellular adenomas: Molecular basis and multimodality imaging update. Radiographics 2023;43(3):e220134.</Citation></Reference><Reference><Citation>Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003;125(5):1470&#x2013;5.</Citation></Reference><Reference><Citation>van Rosmalen BV, Furumaya A, Klompenhouwer AJ, et al. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course. Liver Int 2021;41(10):2474&#x2013;84.</Citation></Reference><Reference><Citation>Silva JP, Klooster B, Tsai S, et al. Elective regional therapy treatment for hepatic adenoma. Ann Surg Oncol 2019;26(1):125&#x2013;30.</Citation></Reference><Reference><Citation>van der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006;93(12):1495&#x2013;502.</Citation></Reference><Reference><Citation>Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228&#x2013;47.</Citation></Reference><Reference><Citation>Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: Take it or leave it? Ann Surg Oncol 2008;15(10):2795&#x2013;803.</Citation></Reference><Reference><Citation>Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: A multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009;16(3):640&#x2013;8.</Citation></Reference><Reference><Citation>Shao N, Pandey A, Ghasabeh MA, et al. Long-term follow-up of hepatic adenoma and adenomatosis: Analysis of size change on imaging with histopathological correlation. Clin Radiol 2018;73(11):958&#x2013;65.</Citation></Reference><Reference><Citation>Klompenhouwer AJ, Sprengers D, Willemssen FE, et al. Evidence of good prognosis of hepatocellular adenoma in post-menopausal women. J Hepatol 2016;65(6):1163&#x2013;70.</Citation></Reference><Reference><Citation>Demory A, P&#xe9;ron JM, Calderaro J, et al. Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation. Hepatology 2023;77(2):430&#x2013;42.</Citation></Reference><Reference><Citation>Klompenhouwer AJ, Br&#xf6;ker MEE, Thomeer MGJ, et al. Retrospective study on timing of resection of hepatocellular adenoma. Br J Surg 2017;104(12):1695&#x2013;703.</Citation></Reference><Reference><Citation>Chun YS, Parker RJ, Inampudi S, et al. Imaging surveillance of hypervascular liver lesions in non-cirrhotic patients. J Gastrointest Surg 2016;20(3):564&#x2013;7.</Citation></Reference><Reference><Citation>Vernuccio F, Ronot M, Dioguardi Burgio M, et al. Long-term evolution of hepatocellular adenomas at MRI follow-up. Radiology 2020;295(2):361&#x2013;72.</Citation></Reference><Reference><Citation>Gordon SC, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105(4):547&#x2013;9.</Citation></Reference><Reference><Citation>Furumaya A, Haring MPD, van Rosmalen BV, et al. Study protocol for a multicentre nationwide prospective cohort study to investigate the natural course and clinical outcome in benign liver tumours and cysts in the Netherlands: The BELIVER study. BMJ Open 2022;12(9):e055104.</Citation></Reference><Reference><Citation>Klompenhouwer AJ, van Rosmalen BV, Haring MPD, et al. A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection. Liver Int 2020;40(9):2272&#x2013;8.</Citation></Reference><Reference><Citation>Landi F, De' Angelis N, Scatton O, et al. Short-term outcomes of laparoscopic vs. open liver resection for hepatocellular adenoma: A multicenter propensity score adjustment analysis by the AFC-HCA-2013 study group. Surg Endosc 2017;31(10):4136&#x2013;44.</Citation></Reference><Reference><Citation>Elfrink AKE, Haring MPD, de Meijer VE, et al. Surgical outcomes of laparoscopic and open resection of benign liver tumours in the Netherlands: A nationwide analysis. HPB (Oxford) 2021;23(8):1230&#x2013;43.</Citation></Reference><Reference><Citation>Smolock AR, Cristescu MM, Potretzke TA, et al. Microwave ablation for the treatment of hepatic adenomas. J Vasc Interv Radiol 2016;27(2):244&#x2013;9.</Citation></Reference><Reference><Citation>van Rosmalen BV, Coelen RJS, Bieze M, et al. Systematic review of transarterial embolization for hepatocellular adenomas. Br J Surg 2017;104(7):823&#x2013;35.</Citation></Reference><Reference><Citation>Crawford D, Naidu S, Patel I, et al. Bland embolization of benign liver tumors: Review of the literature and a single center experience. J Clin Med 2021;10(4):658.</Citation></Reference><Reference><Citation>Gaspersz MP, Klompenhouwer AJ, Broker MEE, et al. Growth of hepatocellular adenoma during pregnancy: A prospective study. J Hepatol 2020;72(1):119&#x2013;24.</Citation></Reference><Reference><Citation>Haring MPD, Spijkerboer CS, Cuperus FJC, et al. Behavior and complications of hepatocellular adenoma during pregnancy and puerperium: A retrospective study and systematic review. HPB (Oxford) 2021;23(8):1152&#x2013;63.</Citation></Reference><Reference><Citation>Krause K, Tanabe KK. A shifting paradigm in diagnosis and management of hepatic adenoma. Ann Surg Oncol 2020;27(9):3330&#x2013;8.</Citation></Reference><Reference><Citation>Stoot JH, van der Linden E, Terpstra OT, et al. Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization. Br J Surg 2007;94(10):1249&#x2013;53.</Citation></Reference><Reference><Citation>Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137(5):1698&#x2013;705.</Citation></Reference><Reference><Citation>Klompenhouwer AJ, de Man RA, Thomeer MG, et al. Management and outcome of hepatocellular adenoma with massive bleeding at presentation. World J Gastroenterol 2017;23(25):4579&#x2013;86.</Citation></Reference><Reference><Citation>Mathew RP, Manolea F, Girgis S, et al. Malignant transformation of hepatic adenoma complicated by rupture and hemorrhage: An extremely rare clinical entity. Intractable Rare Dis Res 2019;8(4):266&#x2013;70.</Citation></Reference><Reference><Citation>Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005;7(3):186&#x2013;96.</Citation></Reference><Reference><Citation>Wellen JR, Anderson CD, Doyle M, et al. The role of liver transplantation for hepatic adenomatosis in the pediatric population: Case report and review of the literature. Pediatr Transplant 2010;14(3):E16&#x2013;9.</Citation></Reference><Reference><Citation>Blanc JF, Frulio N, Chiche L, et al. Hepatocellular adenoma management: Call for shared guidelines and multidisciplinary approach. Clin Res Hepatol Gastroenterol 2015;39(2):180&#x2013;7.</Citation></Reference><Reference><Citation>Chiche L, David A, Adam R, et al. Liver transplantation for adenomatosis: European experience. Liver Transpl 2016;22(4):516&#x2013;26.</Citation></Reference><Reference><Citation>Sundar Alagusundaramoorthy S, Vilchez V, Zanni A, et al. Role of transplantation in the treatment of benign solid tumors of the liver: A review of the United Network of Organ Sharing data set. JAMA Surg 2015;150(4):337&#x2013;42.</Citation></Reference><Reference><Citation>Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exception Review. Organ Procurement and Transplantation Network, 2023.</Citation></Reference><Reference><Citation>Ziogas IA, Tasoudis PT, Serifis N, et al. Liver transplantation for hepatic adenoma: A UNOS database analysis and systematic review of the literature. Transplant Direct 2022;8(2):e1264.</Citation></Reference><Reference><Citation>Vilgrain V, Uzan F, Brancatelli G, et al. Prevalence of hepatic hemangioma in patients with focal nodular hyperplasia: MR imaging analysis. Radiology 2003;229(1):75&#x2013;9.</Citation></Reference><Reference><Citation>Wanless IR, Albrecht S, Bilbao J, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: A new syndrome. Mod Pathol 1989;2(5):456&#x2013;62.</Citation></Reference><Reference><Citation>Libbrecht L, Cassiman D, Verslype C, et al. Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol 2006;101(10):2341&#x2013;6.</Citation></Reference><Reference><Citation>Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000;118(3):560&#x2013;4.</Citation></Reference><Reference><Citation>Ashhab AA, Abu-Sulb A, Yang JD, et al. Estrogen-driven growth of focal nodular hyperplasia: Truth or myth? ACG Case Rep J 2021;8(1):e00531.</Citation></Reference><Reference><Citation>Vanhooymissen I, Thomeer MG, Braun LMM, et al. Intrapatient comparison of the hepatobiliary phase of Gd-BOPTA and Gd-EOB-DTPA in the differentiation of hepatocellular adenoma from focal nodular hyperplasia. J Magn Reson Imaging 2019;49(3):700&#x2013;10.</Citation></Reference><Reference><Citation>Guo Y, Li W, Xie Z, et al. Diagnostic value of Gd-EOB-DTPA-MRI for hepatocellular adenoma: A meta-analysis. J Cancer 2017;8(7):1301&#x2013;10.</Citation></Reference><Reference><Citation>McInnes MD, Hibbert RM, In&#xe1;cio JR, et al. Focal nodular hyperplasia and hepatocellular adenoma: Accuracy of gadoxetic acid-enhanced MR imaging: A systematic review. Radiology 2015;277(2):413&#x2013;23.</Citation></Reference><Reference><Citation>Soussan M, Aub&#xe9; C, Bahrami S, et al. Incidental focal solid liver lesions: Diagnostic performance of contrast-enhanced ultrasound and MR imaging. Eur Radiol 2010;20(7):1715&#x2013;25.</Citation></Reference><Reference><Citation>Bertin C, Egels S, Wagner M, et al. Contrast-enhanced ultrasound of focal nodular hyperplasia: A matter of size. Eur Radiol 2014;24(10):2561&#x2013;71.</Citation></Reference><Reference><Citation>Roche V, Pigneur F, Tselikas L, et al. Differentiation of focal nodular hyperplasia from hepatocellular adenomas with low-mechanical-index contrast-enhanced sonography (CEUS): Effect of size on diagnostic confidence. Eur Radiol 2015;25(1):186&#x2013;95.</Citation></Reference><Reference><Citation>Br&#xf6;ker MEE, Taimr P, de Vries M, et al. Performance of contrast-enhanced sonography versus MRI with a liver-specific contrast agent for diagnosis of hepatocellular adenoma and focal nodular hyperplasia. AJR Am J Roentgenol 2020;214(1):81&#x2013;9.</Citation></Reference><Reference><Citation>Kang TW, Jeong WK, Kim YY, et al. Comparison of super-resolution US and contrast material-enhanced US in detection of the spoke wheel sign in patients with focal nodular hyperplasia. Radiology 2021;298(1):82&#x2013;90.</Citation></Reference><Reference><Citation>LeGout JD, Bolan CW, Bowman AW, et al. Focal nodular hyperplasia and focal nodular hyperplasia-like lesions. Radiographics 2022;42(4):1043&#x2013;61.</Citation></Reference><Reference><Citation>Choi Y, Huh J, Woo DC, et al. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism. Br J Radiol 2016;89(1058):20150666.</Citation></Reference><Reference><Citation>Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: Results of a multicenter trial. Invest Radiol 2008;43(7):504&#x2013;11.</Citation></Reference><Reference><Citation>V&#xe9;die AL, Sutter O, Ziol M, et al. Molecular classification of hepatocellular adenomas: Impact on clinical practice. Hepat Oncol 2018;5(1):Hep04.</Citation></Reference><Reference><Citation>Rowan DJ, Allende DS, Bellizzi AM, et al. Diagnostic challenges of focal nodular hyperplasia: Interobserver variability, accuracy, and the utility of glutamine synthetase immunohistochemistry. Histopathology 2021;79(5):791&#x2013;800.</Citation></Reference><Reference><Citation>Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 2012;36(11):1691&#x2013;9.</Citation></Reference><Reference><Citation>Campos Amico E, de Souza IK, Grig&#xf3;rio Trigueiro JR, et al. Should focal nodular hyperplasia still be operated upon? Analysis of a case series. Dig Dis 2019;37(4):309&#x2013;14.</Citation></Reference><Reference><Citation>Rifai K, Mix H, Krusche S, et al. No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy. Scand J Gastroenterol 2013;48(1):88&#x2013;92.</Citation></Reference><Reference><Citation>Scalori A, Tavani A, Gallus S, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: A case-control study. Am J Obstet Gynecol 2002;186(2):195&#x2013;7.</Citation></Reference><Reference><Citation>Fodor M, Primavesi F, Braunwarth E, et al. Indications for liver surgery in benign tumours. Eur Surg 2018;50(3):125&#x2013;31.</Citation></Reference><Reference><Citation>Zhang G, Wang M, Duan F, et al. Transarterial embolization with bleomycin for symptomatic hepatic focal nodular hyperplasia. Diagn Interv Radiol 2017;23(1):66&#x2013;70.</Citation></Reference><Reference><Citation>Yan JY, Wang MQ, Liu FY, et al. Super selective transcatheter arterial embolization for treatment of focal nodular hyperplasia of the liver: Report of 21 cases [in Chinese]. Zhonghua Yi Xue Za Zhi 2012;92(41):2893&#x2013;6.</Citation></Reference><Reference><Citation>Caseiro-Alves F, Brito J, Araujo AE, et al. Liver haemangioma: Common and uncommon findings and how to improve the differential diagnosis. Eur Radiol 2007;17(6):1544&#x2013;54.</Citation></Reference><Reference><Citation>Klotz T, Montoriol PF, Da Ines D, et al. Hepatic haemangioma: Common and uncommon imaging features. Diagn Interv Imaging 2013;94(9):849&#x2013;59.</Citation></Reference><Reference><Citation>Shaked O, Siegelman ES, Olthoff K, et al. Biologic and clinical features of benign solid and cystic lesions of the liver. Clin Gastroenterol Hepatol 2011;9(7):547&#x2013;62.e1-4.</Citation></Reference><Reference><Citation>Hall GW. Kasabach-Merritt syndrome: Pathogenesis and management. Br J Haematol 2001;112(4):851&#x2013;62.</Citation></Reference><Reference><Citation>O'Rafferty C, O'Regan GM, Irvine AD, et al. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 2015;171(1):38&#x2013;51.</Citation></Reference><Reference><Citation>van Malenstein H, Maleux G, Monbaliu D, et al. Giant liver hemangioma: The role of female sex hormones and treatment. Eur J Gastroenterol Hepatol 2011;23(5):438&#x2013;43.</Citation></Reference><Reference><Citation>Sarkar M, Brady CW, Fleckenstein J, et al. Reproductive health and liver disease: Practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73(1):318&#x2013;65.</Citation></Reference><Reference><Citation>Sandulescu LD, Urhut CM, Sandulescu SM, et al. One stop shop approach for the diagnosis of liver hemangioma. World J Hepatol 2021;13(12):1892&#x2013;908.</Citation></Reference><Reference><Citation>Toro A, Mahfouz AE, Ardiri A, et al. What is changing in indications and treatment of hepatic hemangiomas. A review. Ann Hepatol 2014;13(4):327&#x2013;39.</Citation></Reference><Reference><Citation>Fang L, Zhu Z, Huang B, et al. A comparative study of contrast enhanced ultrasound and contrast enhanced magnetic resonance imaging for the detection and characterization of hepatic hemangiomas. Biosci Trends 2015;9(2):104&#x2013;10.</Citation></Reference><Reference><Citation>Yu JS, Kim MJ, Kim KW, et al. Hepatic cavernous hemangioma: Sonographic patterns and speed of contrast enhancement on multiphase dynamic MR imaging. AJR Am J Roentgenol 1998;171(4):1021&#x2013;5.</Citation></Reference><Reference><Citation>Quaia E, Bertolotto M, Dalla Palma L. Characterization of liver hemangiomas with pulse inversion harmonic imaging. Eur Radiol 2002;12(3):537&#x2013;44.</Citation></Reference><Reference><Citation>Fang L, Huang BJ, Ding H, et al. Contrast-enhanced ultrasound (CEUS) for the diagnosis of hypoechoic hepatic hemangioma in clinical practice. Clin Hemorheol Microcirc 2019;72(4):395&#x2013;405.</Citation></Reference><Reference><Citation>Danila M, Ciocea C, Popescu A, et al. Contrast enhanced ultrasound (CEUS) in hemangiomas: Atypical behavior. Ultraschall Med 2016;37:SL20_5.</Citation></Reference><Reference><Citation>Kim T, Federle MP, Baron RL, et al. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 2001;219(3):699&#x2013;706.</Citation></Reference><Reference><Citation>Itai Y, Ohtomo K, Furui S, et al. Noninvasive diagnosis of small cavernous hemangioma of the liver: Advantage of MRI. AJR Am J Roentgenol 1985;145(6):1195&#x2013;9.</Citation></Reference><Reference><Citation>Stark DD, Felder RC, Wittenberg J, et al. Magnetic resonance imaging of cavernous hemangioma of the liver: Tissue-specific characterization. AJR Am J Roentgenol 1985;145(2):213&#x2013;22.</Citation></Reference><Reference><Citation>Semelka RC, Brown ED, Ascher SM, et al. Hepatic hemangiomas: A multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994;192(2):401&#x2013;6.</Citation></Reference><Reference><Citation>Vilgrain V, Boulos L, Vullierme MP, et al. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics 2000;20(2):379&#x2013;97.</Citation></Reference><Reference><Citation>Doyle DJ, Khalili K, Guindi M, et al. Imaging features of sclerosed hemangioma. AJR Am J Roentgenol 2007;189(1):67&#x2013;72.</Citation></Reference><Reference><Citation>Shim KS, Suh JM, Yang YS, et al. Sclerosis of hepatic cavernous hemangioma: CT findings and pathologic correlation. J Korean Med Sci 1995;10(4):294&#x2013;7.</Citation></Reference><Reference><Citation>Collin P, Rinta-Kiikka I, R&#xe4;ty S, et al. Diagnostic workup of liver lesions: Too long time with too many examinations. Scand J Gastroenterol 2015;50(3):355&#x2013;9.</Citation></Reference><Reference><Citation>Ariba&#x15f; BK, Arda K, Cileda&#x11f; N, et al. Accuracy and safety of percutaneous US-guided needle biopsies in specific focal liver lesions: Comparison of large and small needles in 1300 patients. Panminerva Med 2012;54(3):233&#x2013;9.</Citation></Reference><Reference><Citation>Kim JH, Joo I, Lee JM. Atypical appearance of hepatocellular carcinoma and its mimickers: How to solve challenging cases using gadoxetic acid-enhanced liver magnetic resonance imaging. Korean J Radiol 2019;20(7):1019&#x2013;41.</Citation></Reference><Reference><Citation>Costa AF, Clarke SE, Stueck AE, et al. Benign neoplasms, mass-like infections, and pseudotumors that mimic hepatic malignancy at MRI. J Magn Reson Imaging 2021;53(4):979&#x2013;94.</Citation></Reference><Reference><Citation>Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922&#x2013;65.</Citation></Reference><Reference><Citation>Toro A, Gagner M, Di Carlo I. Has laparoscopy increased surgical indications for benign tumors of the liver? Langenbecks Arch Surg 2013;398(2):195&#x2013;210.</Citation></Reference><Reference><Citation>Jien H, Xiaohua L. Laparoscopic versus open surgery in the treatment of hepatic hemangioma: A meta-analysis. Medicine (Baltimore) 2021;100(8):e24155.</Citation></Reference><Reference><Citation>Di Carlo I, Sofia M, Toro A. Does the psychological request of the patient justify the surgery for hepatic hemangioma? Hepatogastroenterology 2005;52(63):657&#x2013;61.</Citation></Reference><Reference><Citation>Tang T, Wang X, Mao Y, et al. Real-world data on the clinicopathological traits and outcomes of hospitalized liver hemangioma patients: A multicenter study. Ann Transl Med 2021;9(13):1067.</Citation></Reference><Reference><Citation>Duxbury MS, Garden OJ. Giant haemangioma of the liver: Observation or resection? Dig Surg 2010;27(1):7&#x2013;11.</Citation></Reference><Reference><Citation>Donati M, Stavrou GA, Donati A, et al. The risk of spontaneous rupture of liver hemangiomas: A critical review of the literature. J Hepatobiliary Pancreat Sci 2011;18(6):797&#x2013;805.</Citation></Reference><Reference><Citation>Di Carlo I, Koshy R, Al Mudares S, et al. Giant cavernous liver hemangiomas: Is it the time to change the size categories? Hepatobiliary Pancreat Dis Int 2016;15(1):21&#x2013;9.</Citation></Reference><Reference><Citation>Dong Z, Fang K, Sui C, et al. The surgical outcomes and risk factors of giant hepatic haemangiomas: A single centre experience. BMC Surg 2022;22(1):278.</Citation></Reference><Reference><Citation>Wen SQ, Wan M, Len KM, et al. Safety and efficacy of laparoscopic radiofrequency ablation for hepatic hemangiomas: A multicenter retrospective study. Ann Hepatol 2018;17(2):268&#x2013;73.</Citation></Reference><Reference><Citation>Tuxun T, Apaer S, Zhou CM, et al. Surgery vs. observation for liver hemangioma: A systematic review and meta-analysis. Hepatogastroenterology 2014;61(136):2377&#x2013;82.</Citation></Reference><Reference><Citation>Lin B, He Q, Lu Y, et al. Viral hepatitis increases the risk of cholangiocarcinoma: A systematic review and meta-analysis. Transl Cancer Res 2023;12(6):1602&#x2013;16.</Citation></Reference><Reference><Citation>Tang Y, Wang L, Teng F, et al. The clinical characteristics and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: A propensity score matching analysis. Int J Med Sci 2021;18(1):187&#x2013;98.</Citation></Reference><Reference><Citation>Bowlus CL, Arriv&#xe9; L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology 2023;77(2):659&#x2013;702.</Citation></Reference><Reference><Citation>Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 2020;49(1):1&#x2013;33.</Citation></Reference><Reference><Citation>D'Amico G, Uso TD, Del Prete L, et al. Neuroendocrine liver metastases: The role of liver transplantation. Transplant Rev (Orlando) 2021;35(2):100595.</Citation></Reference><Reference><Citation>Hayoz R, Vietti-Violi N, Duran R, et al. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Eur Radiol 2020;30(12):6593&#x2013;602.</Citation></Reference><Reference><Citation>Freitas PS, Janicas C, Veiga J, et al. Imaging evaluation of the liver in oncology patients: A comparison of techniques. World J Hepatol 2021;13(12):1936&#x2013;55.</Citation></Reference><Reference><Citation>Sahani DV, Bajwa MA, Andrabi Y, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg 2014;259(5):861&#x2013;72.</Citation></Reference><Reference><Citation>Bonney GK, Chew CA, Lodge P, et al. Liver transplantation for non-resectable colorectal liver metastases: The International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021;6(11):933&#x2013;46.</Citation></Reference><Reference><Citation>Mart&#xed;nez C, Lai JK, Ramai D, et al. Cancer registry study of malignant hepatic vascular tumors: Hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas. Cancer Med 2021;10(24):8883&#x2013;90.</Citation></Reference><Reference><Citation>Laz&#x103;r DC, Avram MF, Romo&#x15f;an I, et al. Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management. World J Clin Oncol 2019;10(3):110&#x2013;35.</Citation></Reference><Reference><Citation>Frezza AM, Napolitano A, Miceli R, et al. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: A retrospective case series analysis within the Italian Rare Cancers Network. ESMO Open 2021;6(2):100083.</Citation></Reference><Reference><Citation>Virarkar M, Saleh M, Diab R, et al. Hepatic hemangioendothelioma: An update. World J Gastrointest Oncol 2020;12(3):248&#x2013;66.</Citation></Reference><Reference><Citation>Dong Y, Wang WP, Cantisani V, et al. Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma. World J Gastroenterol 2016;22(19):4741&#x2013;9.</Citation></Reference><Reference><Citation>Qiu T, Zhu D, Fu R, et al. Conventional ultrasound and contrast-enhanced ultrasound in hepatic epithelioid hemangioendothelioma: Retrospective evaluation in 20 cases. Front Oncol 2022;12:686650.</Citation></Reference><Reference><Citation>Wang X, Liang P, Lv P, et al. Clinical characteristics and CT features of hepatic epithelioid haemangioendothelioma and comparison with those of liver metastases. Insights Imaging 2022;13(1):9.</Citation></Reference><Reference><Citation>Zhang W, Zhang H, Zhong Y, et al. Novel and specific MRI features indicate the clinical features of patients with rare hepatic tumor epithelioid hemangioendothelioma. Front Oncol 2022;12:729177.</Citation></Reference><Reference><Citation>Mamone G, Miraglia R. The &#x201c;target sign&#x201d; and the &#x201c;lollipop sign&#x201d; in hepatic epithelioid hemangioendothelioma. Abdom Radiol (NY) 2019;44(4):1617&#x2013;20.</Citation></Reference><Reference><Citation>Liu Z, Yi L, Chen J, et al. Comparison of the clinical and MRI features of patients with hepatic hemangioma, epithelioid hemangioendothelioma, or angiosarcoma. BMC Med Imaging 2020;20(1):71.</Citation></Reference><Reference><Citation>Wang W, Liu G, Hu P, et al. Imaging characteristics and prognostic values of hepatic epithelioid hemangioendothelioma on (18)F-FDG PET/CT. Clin Exp Med 2020;20(4):557&#x2013;67.</Citation></Reference><Reference><Citation>Stacchiotti S, Miah AB, Frezza AM, et al. Epithelioid hemangioendothelioma, an ultra-rare cancer: A consensus paper from the community of experts. ESMO Open 2021;6(3):100170.</Citation></Reference><Reference><Citation>Na BG, Hwang S, Ahn CS, et al. Post-resection prognosis of patients with hepatic epithelioid hemangioendothelioma. Ann Surg Treat Res 2021;100(3):137&#x2013;43.</Citation></Reference><Reference><Citation>Brahmbhatt M, Prenner S, Bittermann T. Liver transplantation for hepatic epithelioid hemangioendothelioma is facilitated by exception points with acceptable long-term outcomes. Transplantation 2020;104(6):1187&#x2013;92.</Citation></Reference><Reference><Citation>Kaltenmeier C, Stacchiotti S, Gronchi A, et al. Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. HPB (Oxford) 2022;24(10):1688&#x2013;96.</Citation></Reference><Reference><Citation>Frezza AM, Ravi V, Lo VulloS, et al. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Med 2021;10(8):2645&#x2013;59.</Citation></Reference><Reference><Citation>Glavas D, Bao QR, Scarpa M, et al. Treatment and prognosis of fibrolamellar hepatocellular carcinoma: A systematic review of the recent literature and meta-analysis. J Gastrointest Surg 2023;27(4):705&#x2013;15.</Citation></Reference><Reference><Citation>Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014;343(6174):1010&#x2013;4.</Citation></Reference><Reference><Citation>Vyas M, Hechtman JF, Zhang Y, et al. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol 2020;33(4):648&#x2013;56.</Citation></Reference><Reference><Citation>McDonald JD, Gupta S, Shindorf ML, et al. Elevated serum &#x3b1;-fetoprotein is associated with abbreviated survival for patients with fibrolamellar hepatocellular carcinoma who undergo a curative resection. Ann Surg Oncol 2020;27(6):1900&#x2013;5.</Citation></Reference><Reference><Citation>O'Neill AF, Church AJ, Perez-Atayde AR, et al. Fibrolamellar carcinoma: An entity all its own. Curr Probl Cancer 2021;45(4):100770.</Citation></Reference><Reference><Citation>Anysz-Grodzicka A, Podgorska J, Cieszanowski A. State-of-the-art MR imaging of uncommon hepatocellular tumours: Fibrolamellar hepatocellular carcinoma and combined hepatocellularcholangiocarcinoma. Curr Med Imaging Rev 2019;15(3):269&#x2013;80.</Citation></Reference><Reference><Citation>Palm V, Sheng R, Mayer P, et al. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. Cancer Imaging 2018;18(1):9.</Citation></Reference><Reference><Citation>Dong Y, Wang WP, Mao F, et al. Imaging features of fibrolamellar hepatocellular carcinoma with contrast-enhanced ultrasound. Ultraschall Med 2021;42(3):306&#x2013;13.</Citation></Reference><Reference><Citation>Assi HA, Mukherjee S, Machiorlatti M, et al. Predictors of outcome in patients with fibrolamellar carcinoma: Analysis of the National Cancer Database. Anticancer Res 2020;40(2):847&#x2013;55.</Citation></Reference><Reference><Citation>Ashraf Y, Mostafa MM. Surgery alone versus surgery combined with chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma. Ann Oncol 2019;30(Suppl 9):ix42&#x2013;67.</Citation></Reference><Reference><Citation>Atienza LG, Berger J, Mei X, et al. Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective. J Surg Oncol 2017;115(3):319&#x2013;23.</Citation></Reference><Reference><Citation>Abou-Alfa GK, Mayer R, Venook AP, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma. Oncologist 2020;25(12):e1837&#x2013;45.</Citation></Reference><Reference><Citation>Chen KY, Popovic A, Hsiehchen D, et al. Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors. Cancers (Basel) 2022;14(21):5347.</Citation></Reference><Reference><Citation>Berger R, Dinstag G, Tirosh O, et al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: Complete response after nivolumab and ipilimumab. J Immunother Cancer 2022;10(12):e005620.</Citation></Reference><Reference><Citation>Zeng D, Zeng X, Duan J, et al. Clinical characteristics of primary hepatic angiosarcoma outcomes: A SEER database analysis. Transl Cancer Res 2021;10(1):110&#x2013;25.</Citation></Reference><Reference><Citation>Zeng D, Cheng J, Gong Z, et al. A pooled analysis of primary hepatic angiosarcoma. Jpn J Clin Oncol 2020;50(5):556&#x2013;67.</Citation></Reference><Reference><Citation>Bhaludin BN, Thway K, Adejolu M, et al. Imaging features of primary sites and metastatic patterns of angiosarcoma. Insights Imaging 2021;12(1):189.</Citation></Reference><Reference><Citation>Jiang S, Wu H, Lu M, et al. Surgery and chemotherapy improve the prognosis of primary hepatic angiosarcoma: A retrospective study based on propensity score matched survival analysis. Eur J Surg Oncol 2021;47(3 Pt B):690&#x2013;8.</Citation></Reference><Reference><Citation>Zheng YW, Zhang XW, Zhang JL, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol 2014;29(5):906&#x2013;11.</Citation></Reference><Reference><Citation>Jain P, Cioffi G, Patil N, et al. Primary liver angiosarcoma and factors associated with improved outcomes: An analysis of the national cancer database. J Clin Oncol 2020;38:4.</Citation></Reference><Reference><Citation>Pink D, Andreou D, Bauer S, et al. Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the EVA (evaluation of Votrient in angiosarcoma) phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06). Cancers (Basel) 2021;13(6):1223.</Citation></Reference><Reference><Citation>Sanfelippo PM, Beahrs OH, Weiland LH. Cystic disease of the liver. Ann Surg 1974;179(6):922&#x2013;5.</Citation></Reference><Reference><Citation>Gaines PA, Sampson MA. The prevalence and characterization of simple hepatic cysts by ultrasound examination. Br J Radiol 1989;62(736):335&#x2013;7.</Citation></Reference><Reference><Citation>Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 2003;58(8):626&#x2013;9.</Citation></Reference><Reference><Citation>Larssen TB, R&#xf8;rvik J, Hoff SR, et al. The occurrence of asymptomatic and symptomatic simple hepatic cysts. A prospective, hospital-based study. Clin Radiol 2005;60(9):1026&#x2013;9.</Citation></Reference><Reference><Citation>Marrero JA, Ahn J, Rajender Reddy K. ACG clinical guideline: The diagnosis and management of focal liver lesions. Am J Gastroenterol 2014;109(9):1328&#x2013;47.</Citation></Reference><Reference><Citation>EASL Clinical Practice Guidelines on the management of cystic liver diseases. J Hepatol 2022;77(4):1083&#x2013;108.</Citation></Reference><Reference><Citation>Reid-Lombardo KM, Khan S, Sclabas G. Hepatic cysts and liver abscess. Surg Clin North Am 2010;90(4):679&#x2013;97.</Citation></Reference><Reference><Citation>Lantinga MA, Gevers TJ, Drenth JP. Evaluation of hepatic cystic lesions. World J Gastroenterol 2013;19(23):3543&#x2013;54.</Citation></Reference><Reference><Citation>Erturk SM, Ichikawa T, Kaya E, et al. Diffusion tensor imaging of cysts, hemangiomas, and metastases of the liver. Acta Radiol 2014;55(6):654&#x2013;60.</Citation></Reference><Reference><Citation>Furumaya A, van Rosmalen BV, de Graeff JJ, et al. Systematic review on percutaneous aspiration and sclerotherapy versus surgery in symptomatic simple hepatic cysts. HPB (Oxford) 2021;23(1):11&#x2013;24.</Citation></Reference><Reference><Citation>Qiu JG, Wu H, Jiang H, et al. Laparoscopic fenestration vs open fenestration in patients with congenital hepatic cysts: A meta-analysis. World J Gastroenterol 2011;17(28):3359&#x2013;65.</Citation></Reference><Reference><Citation>Wijnands TF, G&#xf6;rtjes AP, Gevers TJ, et al. Efficacy and safety of aspiration sclerotherapy of simple hepatic cysts: A systematic review. AJR Am J Roentgenol 2017;208(1):201&#x2013;7.</Citation></Reference><Reference><Citation>Saini S, Mueller PR, Ferrucci JT Jr., et al. Percutaneous aspiration of hepatic cysts does not provide definitive therapy. AJR Am J Roentgenol 1983;141(3):559&#x2013;60.</Citation></Reference><Reference><Citation>Choi HK, Lee JK, Lee KH, et al. Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: Significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol 2010;44(4):289&#x2013;93.</Citation></Reference><Reference><Citation>Fuks D, Voitot H, Paradis V, et al. Intracystic concentrations of tumour markers for the diagnosis of cystic liver lesions. Br J Surg 2014;101(4):408&#x2013;16.</Citation></Reference><Reference><Citation>Waters AM, Beales PL. Ciliopathies: An expanding disease spectrum. Pediatr Nephrol 2011;26(7):1039&#x2013;56.</Citation></Reference><Reference><Citation>Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet 2019;393(10174):919&#x2013;35.</Citation></Reference><Reference><Citation>Roediger R, Dieterich D, Chanumolu P, et al. Polycystic kidney/liver disease. Clin Liver Dis 2022;26(2):229&#x2013;43.</Citation></Reference><Reference><Citation>Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009;20(1):205&#x2013;12.</Citation></Reference><Reference><Citation>Drenth JP, Chrispijn M, Nagorney DM, et al. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010;52(6):2223&#x2013;30.</Citation></Reference><Reference><Citation>Chandok N. Polycystic liver disease: A clinical review. Ann Hepatol 2012;11(6):819&#x2013;26.</Citation></Reference><Reference><Citation>Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 2018;29(1):13&#x2013;23.</Citation></Reference><Reference><Citation>Van Keimpema L, De Koning DB, Van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: Clinical characterization of 137 cases. Liver Int 2011;31(1):92&#x2013;8.</Citation></Reference><Reference><Citation>Aapkes SE, Bernts LHP, Barten TRM, et al. Estrogens in polycystic liver disease: A target for future therapies? Liver Int 2021;41(9):2009&#x2013;19.</Citation></Reference><Reference><Citation>Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990;11(6):1033&#x2013;7.</Citation></Reference><Reference><Citation>Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21(6):1052&#x2013;61.</Citation></Reference><Reference><Citation>Pisani A, Sabbatini M, Imbriaco M, et al. Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease. Clin Gastroenterol Hepatol 2016;14(7):1022&#x2013;30.e4.</Citation></Reference><Reference><Citation>Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997;26(5):1282&#x2013;6.</Citation></Reference><Reference><Citation>van Aerts RMM, Bernts LHP, Gevers TJG, et al. Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in premenopausal patients. Clin Pharmacol Ther 2019;106(6):1338&#x2013;45.</Citation></Reference><Reference><Citation>Alsager M, Neong SF, Gandhi R, et al. Liver transplantation in adult polycystic liver disease: The Ontario experience. BMC Gastroenterol 2021;21(1):115.</Citation></Reference><Reference><Citation>Patel A, Chapman AB, Mikolajczyk AE. A practical approach to polycystic liver disease. Clin Liver Dis (Hoboken) 2019;14(5):176&#x2013;9.</Citation></Reference><Reference><Citation>Gamblin TC, Holloway SE, Heckman JT, et al. Laparoscopic resection of benign hepatic cysts: A new standard. J Am Coll Surg 2008;207(5):731&#x2013;6.</Citation></Reference><Reference><Citation>Schnelldorfer T, Torres VE, Zakaria S, et al. Polycystic liver disease: A critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009;250(1):112&#x2013;8.</Citation></Reference><Reference><Citation>van Aerts RMM, Kievit W, D'Agnolo HMA, et al. Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. Gastroenterology 2019;157(2):481&#x2013;91.e7.</Citation></Reference><Reference><Citation>Hogan MC, Masyuk T, Bergstralh E, et al. Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease. Mayo Clin Proc 2015;90(8):1030&#x2013;7.</Citation></Reference><Reference><Citation>Temmerman F, Gevers T, Ho TA, et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: Pooled analysis of individual patient data. Aliment Pharmacol Ther 2013;38(4):397&#x2013;406.</Citation></Reference><Reference><Citation>Temmerman F, Nevens F. Further evidence that lanreotide reduces liver growth in patients with polycystic liver disease, but not the end of the story. Gastroenterology 2019;157(2):298&#x2013;9.</Citation></Reference><Reference><Citation>Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008;19(3):631&#x2013;8.</Citation></Reference><Reference><Citation>Chrispijn M, Gevers TJ, Hol JC, et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: Results from a randomized controlled trial. J Hepatol 2013;59(1):153&#x2013;9.</Citation></Reference><Reference><Citation>D'Agnolo HM, Kievit W, Takkenberg RB, et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol 2016;65(3):601&#x2013;7.</Citation></Reference><Reference><Citation>Averbukh LD, Wu DC, Cho WC, et al. Biliary mucinous cystadenoma: A review of the literature. J Clin Transl Hepatol 2019;7(2):149&#x2013;53.</Citation></Reference><Reference><Citation>Tsui WMS, Adsay NV, Crawford JM, et al. WHO Classification of Tumors of the Digestive System. 4th edn. World Health Organization: Geneva, Switzerland, 2010, pp 236&#x2013;8.</Citation></Reference><Reference><Citation>Quigley B, Reid MD, Pehlivanoglu B, et al. Hepatobiliary mucinous cystic neoplasms with ovarian type stroma (so-called &#x201c;hepatobiliary cystadenoma/cystadenocarcinoma&#x201d;): Clinicopathologic analysis of 36 cases illustrates rarity of carcinomatous change. Am J Surg Pathol 2018;42(1):95&#x2013;102.</Citation></Reference><Reference><Citation>Armutlu A, Quigley B, Choi H, et al. Hepatic cysts: Reappraisal of the classification, terminology, differential diagnosis, and clinicopathologic characteristics in 258 cases. Am J Surg Pathol 2022;46(9):1219&#x2013;33.</Citation></Reference><Reference><Citation>Koffron A, Rao S, Ferrario M, et al. Intrahepatic biliary cystadenoma: Role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery 2004;136(4):926&#x2013;36.</Citation></Reference><Reference><Citation>Devaney K, Goodman ZD, Ishak KG. Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 1994;18(11):1078&#x2013;91.</Citation></Reference><Reference><Citation>Ishak KG, Willis GW, Cummins SD, et al. Biliary cystadenoma and cystadenocarcinoma: Report of 14 cases and review of the literature. Cancer 1977;39(1):322&#x2013;38.</Citation></Reference><Reference><Citation>Regev A, Reddy KR, Berho M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001;193(1):36&#x2013;45.</Citation></Reference><Reference><Citation>Bahirwani R, Reddy KR. Review article: The evaluation of solitary liver masses. Aliment Pharmacol Ther 2008;28(8):953&#x2013;65.</Citation></Reference><Reference><Citation>Budkule DP, Desai GS, Pande P, et al. Infrequent intrahepatic cystic neoplasm: Dilemmas in diagnosis and management. BMJ Case Rep 2019;12(5):e229058.</Citation></Reference><Reference><Citation>Dua MM, Gerry J, Salles A, et al. Biliary cystadenoma: A suggested &#x201c;cystamatic&#x201d; approach? Dig Dis Sci 2016;61(7):1835&#x2013;8.</Citation></Reference><Reference><Citation>Lee MH, Katabathina VS, Lubner MG, et al. Mucin-producing cystic hepatobiliary neoplasms: Updated nomenclature and clinical, pathologic, and imaging features. Radiographics 2021;41(6):1592&#x2013;610.</Citation></Reference><Reference><Citation>Mortele KJ, Ros PR. Benign liver neoplasms. Clin Liver Dis 2002;6(1):119&#x2013;45.</Citation></Reference><Reference><Citation>Soni S, Pareek P, Narayan S, et al. Mucinous cystic neoplasm of the liver (MCN-L): A rare presentation and review of the literature. Med Pharm Rep 2021;94(3):366&#x2013;71.</Citation></Reference><Reference><Citation>Boyum JH, Sheedy SP, Graham RP, et al. Hepatic mucinous cystic neoplasm versus simple biliary cyst: Assessment of distinguishing imaging features using CT and MRI. AJR Am J Roentgenol 2021;216(2):403&#x2013;11.</Citation></Reference><Reference><Citation>Kim HJ, Yu ES, Byun JH, et al. CT differentiation of mucin-producing cystic neoplasms of the liver from solitary bile duct cysts. AJR Am J Roentgenol 2014;202(1):83&#x2013;91.</Citation></Reference><Reference><Citation>Cogley JR, Miller FH. MR imaging of benign focal liver lesions. Radiol Clin North Am 2014;52(4):657&#x2013;82.</Citation></Reference><Reference><Citation>Lewin M, Mourra N, Honigman I, et al. Assessment of MRI and MRCP in diagnosis of biliary cystadenoma and cystadenocarcinoma. Eur Radiol 2006;16(2):407&#x2013;13.</Citation></Reference><Reference><Citation>Aslam A, Wasnik AP, Shi J, et al. Intraductal papillary neoplasm of the bile duct (IPNB): CT and MRI appearance with radiology-pathology correlation. Clin Imaging 2020;66:10&#x2013;7.</Citation></Reference><Reference><Citation>Park HJ, Kim SY, Kim HJ, et al. Intraductal papillary neoplasm of the bile duct: Clinical, imaging, and pathologic features. AJR Am J Roentgenol 2018;211(1):67&#x2013;75.</Citation></Reference><Reference><Citation>Vogt DP, Henderson JM, Chmielewski E. Cystadenoma and cystadenocarcinoma of the liver: A single center experience. J Am Coll Surg 2005;200(5):727&#x2013;33.</Citation></Reference><Reference><Citation>Jwa EK, Hwang S. Clinicopathological features and post-resection outcomes of biliary cystadenoma and cystadenocarcinoma of the liver. Ann Hepatobiliary Pancreat Surg 2017;21(3):107&#x2013;13.</Citation></Reference><Reference><Citation>Song Y, Kang MJ, Jang JY, et al. Clinical outcome and long term results after surgical treatment of biliary cystadenoma and cystadenocarcinoma. Korean J Hepatobiliary Pancreat Surg 2012;16(1):24&#x2013;8.</Citation></Reference><Reference><Citation>Pitchaimuthu M, Aidoo-Micah G, Coldham C, et al. Outcome following resection of biliary cystadenoma: A single centre experience and literature review. Int J Hepatol 2015;2015:382315.</Citation></Reference><Reference><Citation>Lewis WD, Jenkins RL, Rossi RL, et al. Surgical treatment of biliary cystadenoma. A report of 15 cases. Arch Surg 1988;123(5):563&#x2013;8.</Citation></Reference><Reference><Citation>Pinto MM, Kaye AD. Fine needle aspiration of cystic liver lesions. Cytologic examination and carcinoembryonic antigen assay of cyst contents. Acta Cytol 1989;33(6):852&#x2013;6.</Citation></Reference><Reference><Citation>Soares KC, Arnaoutakis DJ, Kamel I, et al. Cystic neoplasms of the liver: Biliary cystadenoma and cystadenocarcinoma. J Am Coll Surg 2014;218(1):119&#x2013;28.</Citation></Reference><Reference><Citation>L&#xe4;uffer JM, Baer HU, Maurer CA, et al. Biliary cystadenocarcinoma of the liver: The need for complete resection. Eur J Cancer 1998;34(12):1845&#x2013;51.</Citation></Reference><Reference><Citation>Klompenhouwer AJ, Ten Cate DWG, Willemssen F, et al. The impact of imaging on the surgical management of biliary cystadenomas and cystadenocarcinomas; a systematic review. HPB (Oxford) 2019;21(10):1257&#x2013;67.</Citation></Reference><Reference><Citation>Redston MS, Wanless IR. The hepatic von Meyenburg complex: Prevalence and association with hepatic and renal cysts among 2843 autopsies [corrected]. Mod Pathol 1996;9(3):233&#x2013;7.</Citation></Reference><Reference><Citation>Da Ines D, Essamet W, Montoriol PF. Peribiliary cysts. Hepatology 2011;54(6):2271&#x2013;2.</Citation></Reference><Reference><Citation>Orii T, Ohkohchi N, Sasaki K, et al. Cholangiocarcinoma arising from preexisting biliary hamartoma of liver--report of a case. Hepatogastroenterology 2003;50(50):333&#x2013;6.</Citation></Reference><Reference><Citation>Xu AM, Xian ZH, Zhang SH, et al. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: Report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2009;21(5):580&#x2013;4.</Citation></Reference><Reference><Citation>Jain D, Sarode VR, Abdul-Karim FW, et al. Evidence for the neoplastic transformation of Von-Meyenburg complexes. Am J Surg Pathol 2000;24(8):1131&#x2013;9.</Citation></Reference><Reference><Citation>Blanc JF, Bernard PH, Carles J, et al. Cholangiocarcinoma arising in Von Meyenburg complex associated with hepatocellular carcinoma in genetic haemochromatosis. Eur J Gastroenterol Hepatol 2000;12(2):233&#x2013;7.</Citation></Reference><Reference><Citation>Nakanuma Y, Kurumaya H, Ohta G. Multiple cysts in the hepatic hilum and their pathogenesis. A suggestion of periductal gland origin. Virchows Arch A Pathol Anat Histopathol 1984;404(4):341&#x2013;50.</Citation></Reference><Reference><Citation>Bazerbachi F, Haffar S, Sugihara T, et al. Peribiliary cysts: A systematic review and proposal of a classification framework. BMJ Open Gastroenterol 2018;5(1):e000204.</Citation></Reference><Reference><Citation>Baron RL, Campbell WL, Dodd GD III. Peribiliary cysts associated with severe liver disease: Imaging-pathologic correlation. AJR Am J Roentgenol 1994;162(3):631&#x2013;6.</Citation></Reference><Reference><Citation>Lee SS, Kim MH, Lee SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004;100(4):783&#x2013;93.</Citation></Reference><Reference><Citation>Kl&#xf6;ppel G, Adsay V, Konukiewitz B, et al. Precancerous lesions of the biliary tree. Best Pract Res Clin Gastroenterol 2013;27(2):285&#x2013;97.</Citation></Reference><Reference><Citation>Ohtsuka M, Shimizu H, Kato A, et al. Intraductal papillary neoplasms of the bile duct. Int J Hepatol 2014;2014:459091.</Citation></Reference><Reference><Citation>Ohtsuka M, Kimura F, Shimizu H, et al. Surgical strategy for mucin-producing bile duct tumor. J Hepatobiliary Pancreat Sci 2010;17(3):236&#x2013;40.</Citation></Reference><Reference><Citation>Brown ZJ, Baghdadi A, Kamel I, et al. Diagnosis and management of choledochal cysts. HPB (Oxford) 2023;25(1):14&#x2013;25.</Citation></Reference><Reference><Citation>Soares KC, Kim Y, Spolverato G, et al. Presentation and clinical outcomes of choledochal cysts in children and adults: A multi-institutional analysis. JAMA Surg 2015;150(6):577&#x2013;84.</Citation></Reference><Reference><Citation>Yamaguchi M. Congenital choledochal cyst. Analysis of 1,433 patients in the Japanese literature. Am J Surg 1980;140(5):653&#x2013;7.</Citation></Reference><Reference><Citation>Huang CS, Huang CC, Chen DF. Choledochal cysts: Differences between pediatric and adult patients. J Gastrointest Surg 2010;14(7):1105&#x2013;10.</Citation></Reference><Reference><Citation>Soares KC, Arnaoutakis DJ, Kamel I, et al. Choledochal cysts: Presentation, clinical differentiation, and management. J Am Coll Surg 2014;219(6):1167&#x2013;80.</Citation></Reference><Reference><Citation>Babbitt DP. Congenital choledochal cysts: New etiological concept based on anomalous relationships of the common bile duct and pancreatic bulb [article in multiple languages]. Ann Radiol (Paris) 1969;12(3):231&#x2013;40.</Citation></Reference><Reference><Citation>Todani T, Watanabe Y, Narusue M, et al. Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 1977;134(2):263&#x2013;9.</Citation></Reference><Reference><Citation>Banks JS, Saigal G, D'Alonzo JM, et al. Choledochal malformations: Surgical implications of radiologic findings. AJR Am J Roentgenol 2018;210(4):748&#x2013;60.</Citation></Reference><Reference><Citation>Hung MH, Lin LH, Chen DF, et al. Choledochal cysts in infants and children: Experiences over a 20-year period at a single institution. Eur J Pediatr 2011;170(9):1179&#x2013;85.</Citation></Reference><Reference><Citation>S&#xf8;reide K, S&#xf8;reide JA. Bile duct cyst as precursor to biliary tract cancer. Ann Surg Oncol 2007;14(3):1200&#x2013;11.</Citation></Reference><Reference><Citation>Sastry AV, Abbadessa B, Wayne MG, et al. What is the incidence of biliary carcinoma in choledochal cysts, when do they develop, and how should it affect management? World J Surg 2015;39(2):487&#x2013;92.</Citation></Reference><Reference><Citation>Chang J, Jang JY, Kang MJ, et al. Clinicopathologic differences in patients with gallbladder cancer according to the presence of anomalous biliopancreatic junction. World J Surg 2016;40(5):1211&#x2013;7.</Citation></Reference><Reference><Citation>Ronnekleiv-Kelly SM, Soares KC, Ejaz A, et al. Management of choledochal cysts. Curr Opin Gastroenterol 2016;32(3):225&#x2013;31.</Citation></Reference><Reference><Citation>Xia HT, Dong JH, Yang T, et al. Extrahepatic cyst excision and partial hepatectomy for Todani type IV-A cysts. Dig Liver Dis 2014;46(11):1025&#x2013;30.</Citation></Reference><Reference><Citation>Fujishiro J, Hori T, Kaneko M, et al. Liver transplantation from a donor with asymptomatic type IV-a choledochal cyst: The long-term postoperative course. Transplantation 2012;94(12):e72.</Citation></Reference><Reference><Citation>Mabrut JY, Kianmanesh R, Nuzzo G, et al. Surgical management of congenital intrahepatic bile duct dilatation, Caroli's disease and syndrome: Long-term results of the French Association of Surgery Multicenter Study. Ann Surg 2013;258(5):713&#x2013;21; discussion 721.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Parasites: Echinococcosis. ( https://www.cdc.gov/parasites/echinococcosis/biology.html ). Accessed March 16, 2023.</Citation></Reference><Reference><Citation>Pakala T, Molina M, Wu GY. Hepatic echinococcal cysts: A review. J Clin Transl Hepatol 2016;4(1):39&#x2013;46.</Citation></Reference><Reference><Citation>Marie C, Petri WA. Echinococcosis. MSD Manual Professional Version. Updated December 2021. ( https://www.msdmanuals.com/professional/infectious-diseases/cestodes-tapeworms/echinococcosis ). Accessed March 16, 2023.</Citation></Reference><Reference><Citation>Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: A systematic review. PLoS Negl Trop Dis 2009;3(9):e524.</Citation></Reference><Reference><Citation>Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010;114(1):1&#x2013;16.</Citation></Reference><Reference><Citation>Govindasamy A, Bhattarai PR, John J. Liver cystic echinococcosis: A parasitic review. Ther Adv Infect Dis 2023;10:20499361231171478.</Citation></Reference><Reference><Citation>Mihmanli M, Idiz UO, Kaya C, et al. Current status of diagnosis and treatment of hepatic echinococcosis. World J Hepatol 2016;8(28):1169&#x2013;81.</Citation></Reference><Reference><Citation>Kantarci M, Bayraktutan U, Karabulut N, et al. Alveolar echinococcosis: Spectrum of findings at cross-sectional imaging. Radiographics 2012;32(7):2053&#x2013;70.</Citation></Reference><Reference><Citation>Tamarozzi F, Silva R, Fittipaldo VA, et al. Serology for the diagnosis of human hepatic cystic echinococcosis and its relation with cyst staging: A systematic review of the literature with meta-analysis. PLoS Negl Trop Dis 2021;15(4):e0009370.</Citation></Reference><Reference><Citation>Tamarozzi F, Longoni SS, Vola A, et al. Evaluation of nine commercial serological tests for the diagnosis of human hepatic cyst echinococcosis and the differential diagnosis with other focal liver lesions: A diagnostic accuracy study. Diagnostics (Basel) 2021;11(2):167.</Citation></Reference><Reference><Citation>Nazligul Y, Kucukazman M, Akbulut S. Role of chemotherapeutic agents in the management of cystic echinococcosis. Int Surg 2015;100(1):112&#x2013;4.</Citation></Reference><Reference><Citation>Akhan O, Erdo&#x11f;an E, Ciftci TT, et al. Comparison of the long-term results of puncture, aspiration, injection and re-aspiration (PAIR) and catheterization techniques for the percutaneous treatment of CE1 and CE3a liver hydatid cysts: A prospective randomized trial. Cardiovasc Intervent Radiol 2020;43(7):1034&#x2013;40.</Citation></Reference><Reference><Citation>Nasseri Moghaddam S, Abrishami A, Malekzadeh R. Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev 2006;2:CD003623.</Citation></Reference><Reference><Citation>Khuroo MS, Dar MY, Yattoo GN, et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: A prospective, randomized study. Gastroenterology 1993;104(5):1452&#x2013;9.</Citation></Reference><Reference><Citation>Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997;337(13):881&#x2013;7.</Citation></Reference><Reference><Citation>Tuxun T, Zhang JH, Zhao JM, et al. World review of laparoscopic treatment of liver cystic echinococcosis: 914 patients. Int J Infect Dis 2014;24:43&#x2013;50.</Citation></Reference><Reference><Citation>Chen X, Chen X, Shao Y, et al. Clinical outcome and immune follow-up of different surgical approaches for human cyst hydatid disease in liver. Am J Trop Med Hyg 2014;91(4):801&#x2013;5.</Citation></Reference><Reference><Citation>Yagci G, Ustunsoz B, Kaymakcioglu N, et al. Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients. World J Surg 2005;29(12):1670&#x2013;9.</Citation></Reference><Reference><Citation>Popa SL, Grad S, Chiarioni G, et al. Applications of artificial intelligence in the automatic diagnosis of focal liver lesions: A systematic review. J Gastrointestin Liver Dis 2023;32(1):77&#x2013;85.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>